The debridement product for patient use is said to be available for clinicians across all 50 US states, DC and Puerto Rico.

BioMonde product manager Katy Nicell said: "Many of the debridement options currently available do not actively, and selectively, remove bacterial burden and all devitalized tissue from a wound. Biosurgery is unique."

BioBag has been developed for the debridement of a wide variety of wounds, including pressure ulcers, neuropathic ulcers, venous stasis ulcers and non-healing traumatic or surgical wounds.

According to the company, BioBag is currently the only FDA cleared contained biosurgical dressing on the market.

BioMonde CEO Gareth Kempson said: "Historically, bio-surgery was reserved for the most challenging wounds that were not responding to conventional treatment.

"In Europe and the UK, we have proven that the early inclusion of BioBag into the routine debridement practice of non-healing wounds, enables rapid results to be achieved in a cost-efficient manner."

Established in 1994, the company manufactured and supplied Larval Therapy in Europe and the UK.

Image: BioMonde has launched its patented biosurgical medical device BioBag. Photo: courtesy of Business Wire.